Search

Your search keyword '"Bianchini, R"' showing total 470 results
Start Over Author "Bianchini, R"
470 results on '"Bianchini, R"'

1. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

Author

Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Jesenak, M., Levi-Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C.A.M., Stellato, C., Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Jesenak, M., Levi-Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C.A.M., and Stellato, C.

Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune-driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence-related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for

Published
2024

2. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

Author

CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Anatomie, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Jesenak, M, Levi-Schaffer, F, Nocentini, G, O'Mahony, L, Palomares, O, Redegeld, F, Sokolowska, M, Van Esch, B C A M, Stellato, C, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Anatomie, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Jesenak, M, Levi-Schaffer, F, Nocentini, G, O'Mahony, L, Palomares, O, Redegeld, F, Sokolowska, M, Van Esch, B C A M, and Stellato, C

Published
2024

3. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

Author

Roth‐Walter, F; https://orcid.org/0000-0001-5005-9228, Adcock, I M; https://orcid.org/0000-0003-2101-8843, Benito‐Villalvilla, C; https://orcid.org/0000-0002-5544-0199, Bianchini, R; https://orcid.org/0000-0003-0351-6937, Bjermer, L; https://orcid.org/0000-0002-3441-8099, Caramori, G; https://orcid.org/0000-0002-9807-327X, Cari, L; https://orcid.org/0000-0003-0698-3872, Chung, K F; https://orcid.org/0000-0001-7101-1426, Diamant, Z; https://orcid.org/0000-0003-0133-0100, Eguiluz‐Gracia, I; https://orcid.org/0000-0002-3774-931X, Knol, E F; https://orcid.org/0000-0001-7368-9820, Jesenak, M; https://orcid.org/0000-0001-7976-2523, Levi‐Schaffer, F; https://orcid.org/0000-0003-0620-2810, Nocentini, G; https://orcid.org/0000-0002-5209-0488, O'Mahony, L; https://orcid.org/0000-0003-4705-3583, Palomares, O; https://orcid.org/0000-0003-4516-0369, Redegeld, F; https://orcid.org/0000-0001-8830-7960, Sokolowska, M; https://orcid.org/0000-0001-9710-6685, Van Esch, B C A M; https://orcid.org/0000-0001-9961-750X, Stellato, C; https://orcid.org/0000-0002-1294-8355, Roth‐Walter, F; https://orcid.org/0000-0001-5005-9228, Adcock, I M; https://orcid.org/0000-0003-2101-8843, Benito‐Villalvilla, C; https://orcid.org/0000-0002-5544-0199, Bianchini, R; https://orcid.org/0000-0003-0351-6937, Bjermer, L; https://orcid.org/0000-0002-3441-8099, Caramori, G; https://orcid.org/0000-0002-9807-327X, Cari, L; https://orcid.org/0000-0003-0698-3872, Chung, K F; https://orcid.org/0000-0001-7101-1426, Diamant, Z; https://orcid.org/0000-0003-0133-0100, Eguiluz‐Gracia, I; https://orcid.org/0000-0002-3774-931X, Knol, E F; https://orcid.org/0000-0001-7368-9820, Jesenak, M; https://orcid.org/0000-0001-7976-2523, Levi‐Schaffer, F; https://orcid.org/0000-0003-0620-2810, Nocentini, G; https://orcid.org/0000-0002-5209-0488, O'Mahony, L; https://orcid.org/0000-0003-4705-3583, Palomares, O; https://orcid.org/0000-0003-4516-0369, Redegeld, F; https://orcid.org/0000-0001-8830-7960, Sokolowska, M; https://orcid.org/0000-0001-9710-6685, Van Esch, B C A M; https://orcid.org/0000-0001-9961-750X, and Stellato, C; https://orcid.org/0000-0002-1294-8355

Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune‐driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence‐related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for st

Published
2024

4. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology

Author

Afd Pharmacology, Pharmacology, Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Jesenak, M., Levi-Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C.A.M., Stellato, C., Afd Pharmacology, Pharmacology, Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Jesenak, M., Levi-Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C.A.M., and Stellato, C.

Published
2024

5. Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology.

Author

Roth‐Walter, F., Adcock, I. M., Benito‐Villalvilla, C., Bianchini, R., Bjermer, L., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguiluz‐Gracia, I., Knol, E. F., Jesenak, M., Levi‐Schaffer, F., Nocentini, G., O'Mahony, L., Palomares, O., Redegeld, F., Sokolowska, M., Van Esch, B. C. A. M., and Stellato, C.

Subjects
LUNG diseases, CELLULAR aging, AGING, TASK forces, CHRONIC obstructive pulmonary disease
Abstract

The accumulation of senescent cells drives inflammaging and increases morbidity of chronic inflammatory lung diseases. Immune responses are built upon dynamic changes in cell metabolism that supply energy and substrates for cell proliferation, differentiation, and activation. Metabolic changes imposed by environmental stress and inflammation on immune cells and tissue microenvironment are thus chiefly involved in the pathophysiology of allergic and other immune‐driven diseases. Altered cell metabolism is also a hallmark of cell senescence, a condition characterized by loss of proliferative activity in cells that remain metabolically active. Accelerated senescence can be triggered by acute or chronic stress and inflammatory responses. In contrast, replicative senescence occurs as part of the physiological aging process and has protective roles in cancer surveillance and wound healing. Importantly, cell senescence can also change or hamper response to diverse therapeutic treatments. Understanding the metabolic pathways of senescence in immune and structural cells is therefore critical to detect, prevent, or revert detrimental aspects of senescence‐related immunopathology, by developing specific diagnostics and targeted therapies. In this paper, we review the main changes and metabolic alterations occurring in senescent immune cells (macrophages, B cells, T cells). Subsequently, we present the metabolic footprints described in translational studies in patients with chronic asthma and chronic obstructive pulmonary disease (COPD), and review the ongoing preclinical studies and clinical trials of therapeutic approaches aiming at targeting metabolic pathways to antagonize pathological senescence. Because this is a recently emerging field in allergy and clinical immunology, a better understanding of the metabolic profile of the complex landscape of cell senescence is needed. The progress achieved so far is already providing opportunities for new therapies, as well as for strategies aimed at disease prevention and supporting healthy aging. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Author

Jensen‐Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels‐Wells, T. R., Dombrowicz, D., Fiebiger, E., Gould, H. J., Irshad, S., Janda, J., Josephs, D. H., Levi‐Schaffer, F., O′Mahony, L., Pellizzari, G., Penichet, M. L., Redegeld, F., Roth‐Walter, F., Singer, J., Untersmayr, E., Vangelista, L., and Karagiannis, S. N.

Published
2018
Full Text
View/download PDF

9. Gezielte Mikronährstoff-Supplementierung in Patientinnen mit Pollenallergie: eine doppelblinde, Placebo-kontrollierte Pilotstudie

Author

Jensen, S., additional, Bartosik, T., additional, Afify, S.M., additional, Bianchini, R., additional, Hufnagl, K., additional, Hofstetter, G., additional, Berger, M., additional, Bastl, M., additional, Berger, U., additional, Rivelles, E., additional, Schmetterer, K., additional, Eckl-Dorna, J., additional, Brkic, F., additional, Vyskocil, E., additional, Guethoff, S., additional, Kramer, M., additional, Jensen-Jarolim, E., additional, and Roth-Walter, F., additional

Published
2022
Full Text
View/download PDF

10. Impact of local back biasing on performance in hybrid FDSOI/bulk high-k/metal gate low power (LP) technology

Author

Fenouillet-Beranger, C., Perreau, P., Benoist, T., Richier, C., Haendler, S., Pradelle, J., Bustos, J., Brun, P., Tosti, L., Weber, O., Andrieu, F., Orlando, B., Pellissier-Tanon, D., Abbate, F., Richard, C., Beneyton, R., Gregoire, M., Ducote, J., Gouraud, P., Margain, A., Borowiak, C., Bianchini, R., Planes, N., Gourvest, E., Bourdelle, K.K., Nguyen, B.Y., Poiroux, T., Skotnicki, T., Faynot, O., and Boeuf, F.

Published
2013
Full Text
View/download PDF

11. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

Author

Bergmann, C, Poli, A, Agache, I, Bianchini, R, Bax, H J, Castells, M, Crescioli, S, Dombrowicz, D, Ferastraoaru, D, Fiebiger, E, Gould, H J, Hartmann, K, Izquierdo, E, Jordakieva, G, Josephs, D H, Jutel, M, Levi-Schaffer, F, de Las Vecillas, L, Lotze, M T, Osborn, G, Pascal, M, Redegeld, F, Rosenstreich, D, Roth-Walter, F, Schmidt-Weber, C B, Shamji, M, Steveling, E H, Turner, M C, Untersmayr, E, Jensen-Jarolim, E, Karagiannis, S N, Bergmann, C, Poli, A, Agache, I, Bianchini, R, Bax, H J, Castells, M, Crescioli, S, Dombrowicz, D, Ferastraoaru, D, Fiebiger, E, Gould, H J, Hartmann, K, Izquierdo, E, Jordakieva, G, Josephs, D H, Jutel, M, Levi-Schaffer, F, de Las Vecillas, L, Lotze, M T, Osborn, G, Pascal, M, Redegeld, F, Rosenstreich, D, Roth-Walter, F, Schmidt-Weber, C B, Shamji, M, Steveling, E H, Turner, M C, Untersmayr, E, Jensen-Jarolim, E, and Karagiannis, S N

Abstract

The immune system interacts with many nominal ‘danger’ signals, endogenous danger-associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)-associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti-cancer immune and targeted therapies. Cross-disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.

Published
2022

12. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

Author

Afd Pharmacology, Pharmacology, Bergmann, C, Poli, A, Agache, I, Bianchini, R, Bax, H J, Castells, M, Crescioli, S, Dombrowicz, D, Ferastraoaru, D, Fiebiger, E, Gould, H J, Hartmann, K, Izquierdo, E, Jordakieva, G, Josephs, D H, Jutel, M, Levi-Schaffer, F, de Las Vecillas, L, Lotze, M T, Osborn, G, Pascal, M, Redegeld, F, Rosenstreich, D, Roth-Walter, F, Schmidt-Weber, C B, Shamji, M, Steveling, E H, Turner, M C, Untersmayr, E, Jensen-Jarolim, E, Karagiannis, S N, Afd Pharmacology, Pharmacology, Bergmann, C, Poli, A, Agache, I, Bianchini, R, Bax, H J, Castells, M, Crescioli, S, Dombrowicz, D, Ferastraoaru, D, Fiebiger, E, Gould, H J, Hartmann, K, Izquierdo, E, Jordakieva, G, Josephs, D H, Jutel, M, Levi-Schaffer, F, de Las Vecillas, L, Lotze, M T, Osborn, G, Pascal, M, Redegeld, F, Rosenstreich, D, Roth-Walter, F, Schmidt-Weber, C B, Shamji, M, Steveling, E H, Turner, M C, Untersmayr, E, Jensen-Jarolim, E, and Karagiannis, S N

Published
2022

21. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Author

Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, Stellato, C, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, and Stellato, C

Abstract

Therapeutic advances using targeted biologicals and small molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell-based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in non-oncological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in non-oncological settings such as cardiovascular disease, obesity and chronic inflammatory disorders. After describing the general features of T cell-based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell-based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

Published
2021

22. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Author

Afd Pharmacology, Pharmacology, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, Stellato, C, Afd Pharmacology, Pharmacology, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, and Stellato, C

Published
2021

23. Immune modulation via T regulatory cell enhancement: disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases - An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Author

CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Anatomie, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, Stellato, C, CTI Research, CTI, MS Dermatologie/Allergologie, Infection & Immunity, Anatomie, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E F, Kolios, Aga, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B, and Stellato, C

Published
2021

24. Investigation of pattern effects in rapid thermal processing technology: modeling

Author

Cacho, Florian, Bono, H., Beneyton, Remi, Dumont, B., Bianchini, R., Colin, Alexis, Fiori, Vincent, and Morin, Pierre

Subjects
Integrated circuit fabrication -- Methods, Annealing -- Research, Annealing -- Methods, Computer-generated environments -- Methods, Computer simulation -- Methods, Semiconductor wafers -- Thermal properties, Integrated circuit fabrication, Business, Computers, Electronics, Electronics and electrical industries
Published
2010

26. Lectotypification. and a new synonym of Bonamia. sericea ( Convolvulaceae): endemic. species from Argentina

Author

MOREIRA, A. L. da C., SIMÃO-BIANCHINI, R., CAVALCANTI, T. B., ANDRÉ LUIZ DA COSTA MOREIRA, UNB, ROSÂNGELA SIMÃO-BIANCHINI, NÚCLEO DE PESQUISA CURADORIA DO HERBÁRIO SP, and TACIANA BARBOSA CAVALCANTI, Cenargen.

Subjects
Especies endémicas, Sinóoimos, Synonym, Lectotipificación, Taxonomia, Endemic species, Lectotypification, Taxonomy
Abstract

Made available in DSpace on 2020-09-24T09:14:03Z (GMT). No. of bitstreams: 1 24823-Texto-del-arti769culo-83773-1-10-20200319.pdf: 9256200 bytes, checksum: 85703dd8e84ceeea58b0384a2811d5f8 (MD5) Previous issue date: 2020

Published
2020

31. EPR kinetic evidence for radical intermediacy in the oxidation of secondary amines to nitrones by [Wo(O2)2OCOC5H4N]-[Bu4N+]

Author

Ballistreri, F.P., Bianchini, R., Pinzino, C., Tomaselli, G.A., and Toscano, R.M.

Subjects
Amines -- Research, Free radical reactions -- Research, Chemicals, plastics and rubber industries
Abstract

Issues concerning the detection and kinetic fate of aminoxyl free radical intermediates in the oxidation reactions of N,N-benzylalkylamines with the anionic oxodiperoxo complex [WO(O2)2OCOC5H4N]-[Bu4N+] are presented.

Published
2000

33. AllergoOncology: microbiota in allergy and cancer - an EAACI position paper

Author

Untersmayr, E, Bax, H J, Bergmann, C, Bianchini, R, Cozen, W, Gould, H J, Hartmann, K, Josephs, D H, Levi-Schaffer, F, Penichet, M L, O'Mahony, L, Poli, A, Redegeld, F A, Roth-Walter, F, Turner, M C, Vangelista, L, Karagiannis, S N, Jensen-Jarolim, E, University of Zurich, and Karagiannis, S N

Subjects
2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published
2019

34. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases

Author

Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Puzzovio, P G, Redegeld, F, Van Esch, B, Stellato, C, Afd Pharmacology, and Pharmacology

Abstract

Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically-based formulation, offering both convenience and lower costs. Aim of this review is to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for chronic inflammatory respiratory diseases. This article is protected by copyright. All rights reserved.

Published
2019

39. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases

Author

Afd Pharmacology, Pharmacology, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Puzzovio, P G, Redegeld, F, Van Esch, B, Stellato, C, Afd Pharmacology, Pharmacology, Roth-Walter, F, Adcock, I M, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, K F, Diamant, Z, Eguiluz-Gracia, I, Knol, E, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Puzzovio, P G, Redegeld, F, Van Esch, B, and Stellato, C

Published
2019

40. A dynamic NMR investigation of the adamantylideneadamantane/Br2 system: kinetic and thermodynamic evidence for reversible formation of the bromonium ion/Brn- pairs

Author

Bellucci, G., Bianchini, R., Chiappe, C., Ambrosetti, R., Catalano, Donata, Bennet, A.J., Slebocka-Tilk, H., Aarts, G.H.M., and Brown, R. S.

Subjects
Magnetic resonance imaging -- Research, Bromine -- Research, Olefins -- Research, Biological sciences, Chemistry
Abstract

A dynamic nuclear magnetic resonance study was made of the adamantylideneadamantane/Br2 system as a function of temperature and excess (Br2). Line shape analysis of the spectral region between delta 2.1 and 2.6 was used to investigate the bromine site exchange rate constants. The results indicated that the dynamic condition occurred through the rate-limiting dissociation of a 1:1 charge-transfer complex to liberate Ad=Ad + Br2.

Published
1993

41. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases

Author

Roth-Walter, F, Adcock, IM, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Caramori, G, Cari, L, Chung, KF, Diamant, Z, Eguiluz-Gracia, I, Knol, E, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Puzzovio, PG, Redegeld, F, Van Esch, B, Stellato, C, Afd Pharmacology, Pharmacology, Wellcome Trust, and Commission of the European Communities

Subjects
CLUSTER-ANALYSIS, Science & Technology, Allergy, PROSTAGLANDIN D-2, Immunology, INNATE LYMPHOID-CELLS, INHIBITOR, CRTH2 ANTAGONIST, asthma, OBSTRUCTIVE PULMONARY-DISEASE, chronic obstructive pulmonary disease, DOUBLE-BLIND, ANTIBODY, COPD, antibodies, biologicals, small molecule drugs, 1107 Immunology, Life Sciences & Biomedicine
Abstract

Chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with their comorbidities, bear a significant burden on public health. Increased appreciation of molecular networks underlying inflammatory airway disease needs to be translated into new therapies for distinct phenotypes not controlled by current treatment regimens. On the other hand, development of new safe and effective therapies for such respiratory diseases is an arduous and expensive process. Antibody-based (biological) therapies are successful in treating certain respiratory conditions not controlled by standard therapies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory respiratory diseases, such as COPD, biologicals are having a more limited impact. Small molecule drug (SMD)-based therapies represent an active field in pharmaceutical research and development. SMDs expand biologicals' therapeutic targets by reaching the intracellular compartment by delivery as either an oral or topically-based formulation, offering both convenience and lower costs. Aim of this review is to compare and contrast the distinct pharmacological properties and clinical applications of SMDs- and antibody-based treatment strategies, their limitations and challenges, in order to highlight how they should be integrated for their optimal utilization and to fill the critical gaps in current treatment for chronic inflammatory respiratory diseases. This article is protected by copyright. All rights reserved.

Published
2018

45. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Author

Jensen-Jarolim, E, Bax, H J, Bianchini, R, Crescioli, S, Daniels-Wells, T R, Dombrowicz, D, Fiebiger, Edda, Gould, H J, Irshad, S, Janda, Jozef, Josephs, D H, Levi-Schaffer, F, O Mahony, L, Pellizzari, G, Penichet, M L, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, Eva, Vangelista, L, Karagiannis, S N, Jensen-Jarolim, E, Bax, H J, Bianchini, R, Crescioli, S, Daniels-Wells, T R, Dombrowicz, D, Fiebiger, Edda, Gould, H J, Irshad, S, Janda, Jozef, Josephs, D H, Levi-Schaffer, F, O Mahony, L, Pellizzari, G, Penichet, M L, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, Eva, Vangelista, L, and Karagiannis, S N

Abstract

While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

Published
2018

46. AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Author

Afd Pharmacology, Pharmacology, Jensen-Jarolim, E, Bax, H J, Bianchini, R, Crescioli, S, Daniels-Wells, T R, Dombrowicz, D, Fiebiger, Edda, Gould, H J, Irshad, S, Janda, Jozef, Josephs, D H, Levi-Schaffer, F, O Mahony, L, Pellizzari, G, Penichet, M L, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, Eva, Vangelista, L, Karagiannis, S N, Afd Pharmacology, Pharmacology, Jensen-Jarolim, E, Bax, H J, Bianchini, R, Crescioli, S, Daniels-Wells, T R, Dombrowicz, D, Fiebiger, Edda, Gould, H J, Irshad, S, Janda, Jozef, Josephs, D H, Levi-Schaffer, F, O Mahony, L, Pellizzari, G, Penichet, M L, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, Eva, Vangelista, L, and Karagiannis, S N

Published
2018

47. Hormesis, cellular stress response, and redox homeostasis in autism spectrum disorders

Author

Calabrese, V., Giordano, J., Ruggieri, M., Berritta, Deja, Trovato, A., Ontario, M. L., Bianchini, R., Calabrese, E. J., and TROVATO SALINARO, Angela

Subjects
Cellular and Molecular Neuroscience, Hormesis, Autism Spectrum Disorder, Stress, Physiological, Physiological, heat shock proteins, vitagenes, Homeostasis, Humans, heme oxygenase, Stress, autism spectrum disorder, hormesis
Abstract

In the United States, 1.1-1.5% of children have been diagnosed with autism spectrum disorders (ASD), corresponding to a 30% increase in incidence and prevalence. Social and communication impairments are the main signs and symptoms of ASD, and currently available medications have been ineffective in reducing these core deficits. Observational studies have indicated that children with ASD tend to show improved cognition and behavior after febrile illness, which is associated with alteration of metabolic pathways, leading to cellular stress responses and increased expression of heat shock proteins (Hsps). Sulforaphane and hydroxytyrosol, phytochemicals derived from cruciferous vegetables and extra virgin olive oil, respectively, can induce metabolic effects in cellular stress responses that are similar to those produced by fever. Thus, modulation of endogenous cellular defense mechanisms may be an innovative approach for therapeutic intervention in ASD and other disorders associated with neuroinflammation and neurodegeneration. This Review introduces the hormetic dose-response concept and presents possible mechanisms and applications for neuroprotection. We address the emerging role of Hsps in the neuroprotective network of redox stress-responsive mechanisms and propose the potential therapeutic utility of the nutritional antioxidants sulforaphane and hydroxytyrosol against particular signs and symptoms of ASD. We argue that such research findings must be approached with pragmatism and prudence. It is vital to capitalize on recent and ongoing investments in brain science research and to refine neuroscientific knowledge and capability for more accurate diagnosis and safe, effective, and ethically sound treatment of ASD and other neuropsychiatric spectrum disorders. © 2016 Wiley Periodicals, Inc.

Published
2016

48. Structural similarities of human and mammalian lipocalins, and their function in innate immunity and allergy

Author

Jensen‐Jarolim, E., Pacios, L.F., Bianchini, R., Hofstetter, G., and Roth‐Walter, F.

Subjects
integumentary system, Protein Conformation, Biología, canine, Review Article, Allergens, Immunoglobulin E, Immunity, Innate, Lipocalins, Immunomodulation, Structure-Activity Relationship, iron, Th2 Cells, Hypersensitivity, Immune Tolerance, Animals, Humans, animal, lipocalin, Review Articles, allergen
Abstract

Owners and their domestic animals via skin shedding and secretions, mutually exchange microbiomes, potential pathogens and innate immune molecules. Among the latter especially lipocalins are multifaceted: they may have an immunomodulatory function and, furthermore, they represent one of the most important animal allergen families. The amino acid identities, as well as their structures by superposition modeling were compared among human lipocalins, hLCN1 and hLCN2, and most important animal lipocalin allergens, such as Can f 1, Can f 2 and Can f 4 from dog, Fel d 4 from cats, Bos d 5 from cow's milk, Equ c 1 from horses, and Mus m 1 from mice, all of them representing major allergens. The β‐barrel fold with a central molecular pocket is similar among human and animal lipocalins. Thereby, lipocalins are able to transport a variety of biological ligands in their highly conserved calyx‐like cavity, among them siderophores with the strongest known capability to complex iron (Fe3+). Levels of human lipocalins are elevated in nonallergic inflammation and cancer, associated with innate immunoregulatory functions that critically depend on ligand load. Accordingly, deficient loading of lipocalin allergens establishes their capacity to induce Th2 hypersensitivity. Our similarity analysis of human and mammalian lipocalins highlights their function in innate immunity and allergy.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results